Drug intelligence / Profile preview

TML-TRA-22

Development stage: Preclinical
Lead developer: Themis Medicare
Modality: Drug Delivery Systems

Overview

TML-TRA-22 is a preclinical-stage antimalarial candidate being developed by Themis Medicare. It is listed in the company's research and development pipeline as an agent for the treatment or prevention of malaria. As of current reporting, the drug is in the preclinical phase, and specific details regarding its molecular target, modality, and formulation have not been fully disclosed. It is part of a series of antimalarial projects at Themis Medicare (such as TML-TRA-19) that focus on long-acting therapeutic profiles, potentially utilizing Novel Drug Delivery Systems (NDDS) to improve pharmacokinetic outcomes.

Other names: TML-TRA-22-Themis Medicare-AntimalarialTML-TRA22-Themis Medicare-AntimalarialTML-TRA 22-Themis Medicare-Antimalarial

Beyond the preview

Go deeper on TML-TRA-22.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TML-TRA-22.

Explore the full profile